Final Results
QUESTER VCT PLC
ANNUAL REPORT 2006
Summary of results for the year ended 28 February 2006
Per Ordinary Share 28 February 28 February 31 January
(pence)
2006 2005 2004
Capital Values
Net asset value 44.5 44.1 50.1
Share price 37.0 44.0 45.0
Return and
Dividends
Interim dividend 1.25 - -
Cumulative dividend 42.8 41.5 41.5
Total Return* 87.3 85.6 91.6
*Net asset value plus cumulative dividend
DIVIDENDS
The directors have proposed a final dividend of 2.5p per share in respect of
the year ending 28 February 2006.
Payment date 3 July 2006
Ex-dividend date 7 June 2006
Associated record date 9 June 2006
CHAIRMAN'S STATEMENT
Overview
This has been an extremely active period
Your Company was merged with Quester VCT 2 plc and Quester VCT 3 plc in June
2005. The principal benefits from the merger have been an increase in the range
and diversity of the portfolio, an improved spread of risk and opportunity, a
reduction in running costs and a flow of dividends as sales are made from a
wider portfolio.
Following the merger, your Board has carried out an energetic and thorough
review of the way in which your Company's strategy will be implemented, within
the guidelines laid down last June. The new Board was augmented by Christopher
Wright, who was previously totally unconnected with Quester Capital Management
Limited ("the Manager"). Within the Manager, Simon Acland has become managing
director.
The two areas reviewed by the Board were the process and timetable for the
realisation of the venture capital portfolio, as it existed at the time of the
merger, and the process of reinvestment of the existing liquid resources and
the proceeds from sale. This led naturally to an assessment of dividends and
dividend policy.
Realisations
The merger documents indicated that the portfolio was mature and largely ready
for realisation. It is expected that it will be substantially realised over the
next three years, depending on favourable conditions continuing for companies
in our sectors.
The pace of realisations has been strong with over £10million realised in the 8
months since the merger, representing about one quarter of the portfolio by
value. Footfall Limited was sold for a profit of £2.7million; 90% over its
merger value. However, there were also disappointments, particularly in the
failure of Anadigm Limited to meet its targets in the second half of last year,
resulting in a loss of £0.7million. Overall net profits of £3.1million have
been realised from the Venture Capital portfolio in this period, which
represents an encouraging first year for the realisation process.
Building a new portfolio
Your Board also re-examined your Manager's position in the market place, and
tested its ability to reinvest the portfolio in a broad range of companies
within its areas of expertise and to build a portfolio with attractive
investment characteristics. While these sectors were disappointing from 2001 to
2005, Quester's performance in the late 80s to mid 90s, before VCTs existed,
and for VCTs from 1995 to 2001, gives your Board comfort that good returns can
be made. The Manager's skills are recognised by professional investors in its
institutional fund. The Manager will be able to take a disciplined approach,
avoiding over valued or hyped situations, and intends to create a spread of
risk across sectors, balancing early versus later stages of maturity. The Board
expects that the current period may prove to be an advantageous time in the
cycle for investment in these sectors.
Quester is one of a limited number of early stage investors with a long and
deep understanding of the information and technology sector, including
biotechnology and related pharmaceutical businesses. Your Board emphasises that
this expertise and the new portfolio which is being built, will continue in the
main to be focused in these areas and that it is possible to earn good returns
from such a portfolio. The individual investments are high risk, but the size
of your Company will enable a reasonable spread of investments to be made.
These high return opportunities may lead to disappointments and losses. It is
also clear that good overall returns will take a number of years to come
through. Since losses tend to be suffered before the high returns from
successful companies, there are likely to be a few years of dull performance
and it is only in the longer term that shareholders can expect to be able to
benefit from the overall performance of the new portfolio.
An amount of £6million has been invested in the year. Of this, £4.7million was
invested in ten new investments with the balance of £1.3million being provided
as further funding to five existing companies.
The change in net assets for the whole year, including the period prior to the
merger, is summarised in the table below
£'000 Pence per
share
Net asset value at 28 February 2005 14,651 44.1
Pre-merger Formula Asset Value ("FAV") adjustment, (221) (0.7)
including merger costs
Merger FAV 14,430 43.4
Assets acquired on merger, net of costs 38,599 (0.3)
Net realised gains on venture capital investments 3,085 3.4
Net unrealised loss on venture capital investments (1,558) (1.7)
Net gains on listed equities and bonds 1,529 1.7
Income less operating expenses (194) (0.3)
Dividends paid, less amounts reinvested (1,479) (1.8)
Share buy-backs (1,077) 0.1
Net asset value at 28 February 2006 53,335 44.5
Board Changes
Simon Bakewell, who had served on the Board since the Company's inception in
1996, retired following the merger. I joined the Board (having been Chairman of
Quester VCT 2) and Christopher Wright, who has extensive experience in early
stage investing, joined the Board in July 2005. Tom Scruby, who had served as
chairman of the Board from 1996 up to the merger, is to retire at the
forthcoming AGM. Tom has continued to provide wise counsel over this period,
based on his understanding of early stage investing. On behalf of the Board, I
would like to express my thanks to both Simon and Tom for their valuable
contribution.
Dividend policy and dividends
Following the merger, your Company held a portfolio of listed equities valued
at £15.6million, which has subsequently been sold down to £11.0million at the
year end. This portfolio is held, together with a small portfolio of bonds, to
provide reserves to meet the further investment needs of the venture capital
portfolio. The reduction in the listed equity portfolio reflects a reduced need
for reserves arising partly from the merger. The Company's liquid resources
have been further augmented by the proceeds of realisations and amounted to
about half of your Company's net assets at the year end. While a substantial
proportion of these funds are likely to be reinvested, there is also ample
scope to pay dividends.
HM Revenue & Customs has recently indicated it will toughen up on the rule
requiring the investment of a fixed proportion of the portfolio, namely 70%, in
venture capital investments. This change will become effective by 6 April 2007.
As the Manager intends to continue to apply a measured approach to
reinvestment, the Board currently expects to pay out useful dividends over the
next few years to satisfy this requirement. The rate will fluctuate depending
on the continuing pace of realisations, the rate of reinvestment and the need
to maintain reserves to back the new portfolio. It currently expects to pay
interim and final dividends. In accordance with VCT rules, these dividends
would be tax free.
You will be aware that, post merger, the Manager's incentive is structured to
reward payouts over the period to February 2009, the minimum target being
aggregate dividends totalling 20% of post merger FAV over that period, with a
higher hurdle of 40% for an increased payment.
An interim dividend of 1.25p per share was paid last November, at a cost of £
1.5million. In the light of all the factors above, your Board has decided to
recommend payment of a final dividend of 2.5p per share, costing approximately
£3million.
Jock Birney
Chairman
17 May 2006
INVESTMENT MANAGER'S REPORT
Introduction
Following the merger in June 2005, we have been focusing our efforts in three
areas: the realisation of a number of our earlier investments, supporting the
companies within the portfolio and identifying new investment opportunities. It
has been an extremely active period for the venture capital portfolio: several
exits have been achieved and we have made good progress with new investments.
The venture capital portfolio has recorded overall positive returns for the
year; the unquoted element of the portfolio generated net gains of £2.0million
whilst the quoted portion of the portfolio showed a loss of £0.5million.
We believe that the prospects for the technology sector are improving, as
evidenced by much increased M&A activity and improved sentiment towards AIM,
and this should continue through the current year. We believe that we are
therefore in a more favourable climate for early stage venture capital
investment than in recent years.
Realisation from the venture capital portfolio
The year to 28 February 2006 has been an extremely active period for the
portfolio in terms of sales achieved. We realised ten investments, either
wholly or in part, generating cash proceeds of
£10.5million and a gain of £2.9million over merger FAV, as detailed below:
Company Cash proceeds Merger FAV Gain/loss over
merger FAV
£'000 £'000 £'000
Anadigm Limited - 729 (729)
Casella Group Limited 1,121 1,121 -
Crown Sports plc 440 435 5
Dycem Limited 408 373 35
Footfall Limited 5,630 2,900 2,730
HTC Healthcare Group plc 120 120 -
International Resources Group 925 400 525
plc
Loudeye Corp. 1,491 1,204 287
Sirius Financial Solutions plc 128 122 6
XKO Group plc 271 232 39
10,534 7,636 2,898
We reported on the sales of Anadigm, Casella, Loudeye and Crown Sports at the
interim stage. The significant sales achieved since the half year are:
• Footfall, the leading provider of customer counting technology and statistics
to both the retail and retail property sectors, was sold to Experian, the
information solutions company, for over £35million. This was the most
significant exit for Quester VCT during the year generating proceeds of £
5.6million, a profit of £2.7million and an IRR of 13%.
• The residual holding in International Resources Group, which trades as Odgers
Ray & Berndtson, a leading executive search firm, was sold during the period.
This investment was made in 1998 and returned a total of £1.7million, including
income, on a cost of £0.4million, generating an IRR of 42%.
• The disposal of Dycem, a leading manufacturer of quality non-slip products
addressing a number of stabilisation and gripping problems and a pioneer of
contamination control flooring solutions has resulted in overall cash proceeds,
inclusive of income, of £1.5million on an original cost of £0.7million giving
rise to an IRR of 14%.
Venture Capital Investments made during the year
We continue to seek new venture capital investments. The selection process for
new investment opportunities is structured so that only those investments with
the greatest potential are chosen. It would certainly be possible to accelerate
the rate of investment by being less selective: however, we believe that this
would compromise quality and ultimately returns to investors.
Company Industry sector £'000
Cluster Seven Limited Software 743
Genosis plc Diagnostics & devices 1,140
Global Silicon Limited Semiconductors 600
Haemostatix Limited Biotechnology 53
Lectus Therapeutics Limited Biotechnology 248
Level Four Software Limited Software 518
Nanotecture Limited Industrial products & 25
services
PanOpSys Limited Diagnostics & devices 240
Pelikon Limited Electronics 708
Perpetuum Limited Electronics 435
4,710
A number of these investments are made on a tranched basis, with each tranche
subject to milestones being met. This is a deliberate strategy and appropriate
reserves are maintained to fund the additional tranches of investment. This
retention of reserves is an integral aspect of early stage venture capital
investment, as it ensures the ability to continue to back investments, as and
when further funding is required.
We reported on the new investments in Global Silicon, Level Four Software,
Nanotecture and Pelikon in the interim report. The new investments made
subsequent to the half year are covered below:
• Cluster Seven develops and sells enterprise spreadsheet management software.
The company's products provide control over spreadsheets being used in mission
critical environments. In the current regulatory environment, the control of
spreadsheets is paramount and there is a substantial global market for Cluster
Seven's products. The company has built an impressive client base, principally
in the UK, and the £2.4million first round funding will be invested in product
development and expansion in the US. Henry Sallitt, a Quester director, has
joined its board.
• Genosis focuses on developing innovative and unique solutions for the
diagnosis of reproductive disorders. This is a growing market with an estimated
1 in 6 couples globally experiencing fertility issues. Genosis' first product,
Fertell, is a combined male and female home fertility test available
exclusively over-the-counter at Boots. Quester VCT's initial investment was a
pre-AIM investment. The company subsequently raised £7million on its admission
to trading on AIM in December enabling manufacturing capabilities to be scaled
up and marketing and sales resources to be enhanced.
• Haemostatix is a drug discovery company concentrating on the development of
an alternative to blood platelet transfusion. Its product, HaemoPlaxTM, is
designed to be a safer and more cost effective alternative to existing
procedures. In January, Quester led a £3.1million investment in Haemostatix,
which will enable the company to finance the development of HaemoPlax through
to preliminary clinical trials and also advance its pipeline of follow-on
products. Jonathan Gee, a Quester director, has joined its board.
• Lectus Therapeutics specialises in the discovery and development of novel
drugs (ion channel modulators) for diseases associated with pain management,
urinary incontinence and angina, offering important clinical and economic
advantages over existing therapies in this growing market. The company raised £
8.2million in the Series A funding in which Quester VCT participated alongside
leading French venture capital firm Sofinnova and the top two Japanese
pharmaceutical firms, Takeda and Astellas. The new funds will be used to
advance existing programmes and provide opportunities for commercial
partnerships with pharmaceutical companies.
• PanOpSys is a medical diagnostics company specialising in the development of
innovative diagnostic devices to be used to speed up diagnosis and improve
healthcare delivery at the point of care. The company is at an exciting stage
in the commercialisation of its patented piezofilm technology in a growing
market. The company raised £3million in a Series `A' funding led by Quester.
These funds will be used to develop a range of rapid, sensitive, whole blood
immunoassay based products for the measurement of clinically critical markers
in non-laboratory settings. Iain Wilcock, a Quester director, has joined its
board.
• Perpetuum produces electromechanical vibration energy harvesting
micro-generators to power wireless sensor nodes, eliminating the need for hard
wiring or batteries. This technology addresses the growing and substantial
market for wireless sensor systems, which are used for a wide range of
applications. The Quester led £2.2million Series `A' funding round will enable
the company to begin commercialising its technology. Henry Sallitt has joined
the board.
The majority of these new investments are shared with Quester's institutional
fund, Quester Venture Partnership. Several of these investments have also been
seed funded by Quester managed university linked funds, as part of Quester's
proactive deal sourcing strategy.
We have also supported the existing portfolio with five further follow-on
investments totalling £1.3million:
Company Industry sector £'000
Advanced Valve Technologies Industrial products & 261
Limited services
Anthropics Technology Limited Communications 25
Avidex Limited Biotechnology 69
HTC Healthcare Group plc Consumer services 811
Teraview Limited Diagnostics & devices 125
1,291
Developments in the venture capital portfolio
A number of companies have made positive progress since we reported at the half
year.
The valuations of the investments in Methuen Publishing Limited and Sibelius
Software Limited have been marked-up by £344,000 and £62,000 respectively to
reflect the perceived fair value of these investments.
Allergy Therapeutics plc, the AIM quoted company that develops and sells
allergy vaccines, has recently released positive news about one of its
products, Pollinex, progressing into phase III trials. The market has responded
positively to this news resulting in an initial 20% uplift in the share price.
The company has raised a further £19million and, encouraged by the progress
made and future prospects, we made a further £200,000 investment in April 2006.
Avidex Limited, a biotechnology company focused on the novel development of
therapeutics involving T-cell receptors leading to the treatment of cancer,
inflammation and autoimmune diseases, has secured further funding via a
significant investment from a new trade partner, Syngenta. This further funding
will take the company through to the next stage of its development and
demonstrates the progress made with its science, although the fair value of the
investment has been reduced by £326,000 to reflect the pricing of this third
party investment.
Cyclacel Limited has successfully merged with Xcyte Therapies, Inc. to form a
larger international biopharmaceutical company, Cyclacel Pharmaceuticals, Inc.,
a publicly-traded company with a franchise in one of the most exciting fields
of biology, a development-stage portfolio of targeted oncology drug candidates
affecting the cancer cell cycle and holding approximately $20million in cash.
The fair value of the investment in Cyclacel has been reduced by £437,000 to
reflect its implied valuation based upon the market valuation of Cyclacel
Pharmaceuticals, Inc.
These latter two valuation changes reflect current valuation trends across the
biotechnology sector generally, as opposed to specific performance issues with
the individual businesses themselves.
The investment in Linguaphone, previously valued at £299,000, has been written
off.
Sector spread
The spread of sectors covered by the portfolio at 28 February 2006 is provided
in the table below:
Industry sector Percentage of
venture capital
portfolio at Number of
valuation Valuation investments
% £'000
Software 32.0 7,611 11
Diagnostics & devices 12.2 2,901 4
Internet 11.6 2,748 2
Biotechnology 11.4 2,708 6
Consumer services 7.0 1,664 1
Publishing 6.2 1,463 1
Electronics 6.0 1,411 3
Industrial products & services 5.4 1,295 3
Communications 4.3 1,029 2
Semiconductors 3.9 938 2
100.0 23,768 35
We will endeavour to keep a spread of investments in the portfolio so as to
maintain a balance between early stage, higher risk, investments with potential
high returns and later stage, lower risk, investments with correspondingly
lower returns. However, given that this is a venture capital portfolio, it
should be noted that all investments will remain relatively high risk.
Listed equity and bond portfolios
The listed equity portfolio has performed well over the year generating a total
return of 29.3%. The FTSE All Share Index generated a return of 22.3% over the
same period. During the year, the opportunity was taken to reduce the weighting
of this portfolio in relation to the net assets of the Company and a number of
investments were realised. At 28 February 2006, this portfolio was valued at £
11million and was showing an unrealised gain of £1.1million.
The Company retains a small bond portfolio effectively valued at par at £
2.3million. Over the year, this portfolio has provided a yield of approximately
4.6%.
Costs
A key objective of the merger was a reduction in running costs. Annualised post
merger running costs, amounted to 3.0% of closing net assets. This compares
favourably with the percentage for the prior year of 3.9%.
Outlook
Through the merger we achieved our objectives of increasing the range and
diversity of the venture capital portfolio, an increasing pace of realisations
and a reduction in running costs. We have subsequently concentrated on
supporting companies within the portfolio, realising earlier investments and
making investments in a cross section of exciting new companies. We have made
good progress and will continue to concentrate our efforts in these areas in
the current year.
The prospects for the technology sector are improving and the climate is more
favourable for early stage venture capital investment. We are optimistic that
the investments we are now making will deliver attractive returns in the medium
to longer term.
Quester
17 May 2006
Fund Summary as at 28 February 2006
Industry sector Original
Cost Valuation Equity % of fund
£'000 £'000 % held by value
Quoted venture capital investments
Allergy Therapeutics Biotechnology 572 603 1.1% 1.1%
plc
Genosis plc Diagnostics & 1,140 1,113 6.5% 2.1%
devices
Imagesound plc Software 1,848 541 12.4% 1.0%
Sopheon plc Software 178 43 0.2% 0.1%
Surfcontrol plc Software 493 669 0.4% 1.3%
Vernalis plc Biotechnology 886 1,166 0.5% 2.2%
XKO Group plc Software 611 704 1.4% 1.3%
Total quoted venture capital investments 5,728 4,839 9.1%
Unquoted venture capital investments
Advanced Valve Industrial products 2,752 610 12.8% 1.1%
Technologies Limited & services
Antenova Limited Semiconductors 1,004 1,004 5.4% 1.9%
Anthropics Technology Communications 95 25 7.0% -
Limited
Arithmatica Limited Semiconductors 338 338 12.5% 0.6%
Artisan Software Tools Software 2,100 1,173 23.4% 2.2%
Limited
Avidex Limited Biotechnology 602 275 1.4% 0.5%
Casella Group Limited Industrial products 1,389 598 15.8% 1.1%
& services
Cluster Seven Limited Software 743 743 9.3% 1.4%
Community Internet Internet 1,015 634 17.4% 1.2%
Europe Limited
Cyclacel Limited Biotechnology 800 363 1.1% 0.7%
Elateral Holdings Software 2,125 245 24.4% 0.5%
Limited
Global Silicon Limited Semiconductors 600 600 7.6% 1.1%
Haemostatix Limited Biotechnology 53 53 3.6% 0.1%
HTC Healthcare Group Consumer services 2,207 1,664 36.7% 3.1%
plc
International Diagnostics & 1,176 690 23.9% 1.3%
Diagnostics Group plc devices
Lectus Therapeutics Biotechnology 248 248 7.0% 0.5%
Limited
Level Four Software Software 518 518 9.3% 1.0%
Limited
Lorantis Holdings Biotechnology 625 625 1.7% 1.2%
Limited
Methuen Publishing Publishing 1,119 1,463 43.7% 2.7%
Limited
Nanotecture Limited Industrial products 87 87 0.8% 0.2%
& services
Nomad Software Limited Software 1,818 887 18.7% 1.7%
Opsys Management Electronics 1,561 268 - 0.5%
Limited
PanOpSys Limited Diagnostics & 240 240 9.1% 0.5%
devices
Perpetuum Limited Electronics 435 435 8.0% 0.8%
Pelikon Liimted Electronics 708 708 5.5% 1.3%
Sibelius Software Software 1,400 1,463 12.0% 2.7%
Limited
Sift Group Limited Internet 2,260 2,114 14.4% 4.0%
Teraview Limited Diagnostics & 858 858 4.9% 1.6%
devices
Total unquoted venture capital investments 28,876 18,929 35.5%
Total venture capital 34,604 23,768 44.6%
investments
Listed fixed interest 2,302 2,302 4.3%
investments
Listed equity 9,969 11,035 20.7%
investments
Total investments 46,875 37,105 69.6%
Cash and other net 16,230 16,230 30.4%
current assets
Net assets 63,105 53,335 100.0%
The respective cost of investments shown above represents the post merger cost
to Quester VCT plc. This reflects the original cost of the Company's
investments held immediately prior to the merger with Quester VCT 2 plc and
Quester VCT 3 plc together with the merger value of those investments assumed
from Quester VCT 2 and Quester VCT 3 on the merger.
Profit and loss account
For the year ended 28 February 2006
Notes 2005
(13 months)
2006 Restated
£'000 £'000
Gain/(loss) on fair value through 1 3,056 (1,128)
profit or loss on investments
Loss on fair value through profit or - (750)
loss on debtors
Income 2 1,070 457
Investment management fee 3 (778) (331)
Other expenses 4 (486) (285)
Profit/(loss) on ordinary activities 2,862 (2,037)
before taxation
Tax on profit/(loss) on ordinary 6 - -
activities
Profit/(loss) on ordinary activities 2,862 (2,037)
after taxation
Basic and diluted profit/(loss) per 8 3.3p (5.9)p
share
All items in the above statement derive from continuing operations.
The Company has only one class of business and derives its income from
investments made in shares and securities and from bank deposits.
The assets and liabilities of Quester VCT 2 plc and Quester VCT 3 plc were
acquired by means of a Scheme of Arrangement during the year. The acquisition
method of accounting has been adopted.
The accompanying notes are an integral part of this statement.
Note of historical cost profits and losses
For the year ended 28 February 2006
2005
(13 months)
2006 Restated
£'000 £'000
Reported loss on ordinary activities 2,862 (2,037)
before taxation
Realisation of prior year's net 429 (5,155)
unrealised gains/(losses) on
investments
Historical cost loss on ordinary 3,291 (7,192)
activities before taxation
Historical cost loss for the period 3,291 (7,192)
The accompanying notes are an integral part of this statement.
BALANCE SHEET
As at 28 February 2006
2005
(13 months)
2006 Restated
Note £'000 £'000
Fixed assets
Investments 37,105 12,677
Current assets
Debtors 1,095 793
Cash at bank 15,693 1,518
16,788 2,311
Creditors (amounts falling due within (558) (337)
one year)
Net current assets 16,230 1,974
Net assets 53,335 14,651
Capital and reserves
Called-up equity share capital 5,992 1,661
Share premium account 37,359 3,410
Capital redemption reserve 260 112
Special reserve 4,348 7,900
Fair value reserve (2,477) (1,474)
Profit and loss account 7,853 3,042
Total equity shareholders' funds 53,335 14,651
Net asset value per share 9 44.5p 44.1p
The financial statements were approved by the directors on 17 May 2006 and were
signed on their behalf by:
Jock Birney
Chairman
The accompanying notes are an integral part of this statement.
CASHFLOW STATEMENT
For the year ended February 2006
2005
(13 months)
2006 Restated
£'000 £'000
Cash inflow/(outflow) from operating 96 (92)
activities
Financial investment
Purchase of venture capital investments (6,001) (864)
Purchase of listed equities and fixed interest (1,508) (2,962)
securities
Sale/redemption of venture capital investments 9,868 850
Sale/redemption of listed equity and fixed 8,190 3,240
interest securities
Amounts recovered from investments previously 166 -
written-off
Total financial investment 10,715 264
Mergers and acquisitions
Funds received as part of the merger 6,141 -
Merger costs (220) -
Total mergers and acquisitions 5,921 -
Equity dividends paid
Equity dividends paid net of amounts re- (1,480) -
invested through Dividend Reinvestment Scheme
Financing
Buy back of shares (1,077) (370)
Increase/(decrease) in cash for the period 14,175 (198)
Reconciliation of net cash flow to movement
in net funds
Increase/(decrease) in cash for the period 14,175 (198)
Net funds at the start of the period 1,518 1,716
Net funds at the end of the period 15,693 1,518
The accompanying notes are an integral part of this statement.
Reconciliation of movement in shareholders' funds
For the year ended 28 February 2006
Share Share Capital Special Fair Profit and Total
capital premium redemption reserve value loss
account reserve reserve account
£'000 £'000 £'000 £'000 £'000 £'000 £'000
At 1 March 2005 1,661 3,410 - 8,012 (1,474) 3,042 14,651
Effect of - - 112 (112) - - -
creating a
capital
redemption
reserve
- At 1 March 1,661 3,410 112 7,900 (1,474) 3,042 14,651
2005 (restated)
Shares issued in 4,473 34,126 - - - - 38,599
connection with
the merger
Shares issued 6 43 - - - - 49
under the
Dividend
Reinvestment
Scheme
Shares purchased (148) - 148 (1,077) - - (1,077)
for cancellation
Merger costs - (220) - - - - (220)
Realisation of - - - - (429) 429 -
prior years' net
unrealised gains
on investments
Profit on - - - - - 2,862 2,862
ordinary
activities after
taxation
Unrealsied loss - - - - (574) 574 -
on revaluation
of investments
Transfer from - - - (2,475) - 2,475 -
special reserve
to profit and
loss account
Interim dividend - - - - - (1.529) (1,529)
paid
At 28 February 5,992 37,359 260 4,348 (2,477) 7,853 53,335
2006
NOTES TO THE FINANCIAL STATEMENTS
1. Gain/(loss) on fair value through profit or loss on investments
2005
2006 (13 months)
£'000 £'000
Net gain on disposal 4,193 (14)
Write-off of investments (729) (839)
Write-down of debtors - (91)
Recoveries made in respect of investments previously 166 51
written-off
Unrealised loss on revaluation of investments (574) (235)
3,056 (1,128)
2. Income
2005
2006 (13 months)
£'000 £'000
Dividend income
Unlisted companies 228 37
Listed companies 405 92
Interest receivable
Fixed interest securities 162 125
Loans to unquoted companies 124 154
Bank deposits 82 39
Other income 69 10
1,070 457
3. Investment management fee
2005
2006 (13 months)
£'000 £'000
Investment management fee 778 331
Irrecoverable VAT 104 37
882 368
Quester Capital Management Limited ("QCML") provides investment management
services to the Company under an amended and restated management agreement
dated 20 May 2005.
QCML is a wholly owned subsidiary of Querist Limited, a company in which APG
Holmes is a beneficial shareholder. APG Holmes is an executive director of
QCML.
Prior to the merger, QCML was entitled to receive an annual management fee,
payable quarterly in arrears, at the rate of 2.5% on the value of the audited
net assets of the Company as at the end of the previous accounting period. This
fee was capped to ensure that the Company's running costs did not exceed 3.25%
of closing net asset value. Following the merger, QCML is entitled to receive a
management fee, determined quarterly in arrears, at the annual rate of 2.0% on
the value of the Company's net assets at the end of each quarter. This new fee
is similarly capped to ensure that the Company's running costs do not exceed
3.25% of closing net asset value. The management fee for the year amounted to £
778,000 (2005: £331,000). This is stated net of an amount of £9,000 (2005: £
116,000) being a reduction to achieve the necessary cap on running costs.
Upon the Company having paid or declared cash dividends (excluding 1.0p of the
special interim dividend paid post merger) of an aggregate amount equal to 20%
or more of the Company's Formula Asset Value (net of 1.0p of the special
interim dividend) multiplied by the number of ordinary shares in issue
immediately following the merger ("the FAV") by 28 February 2009, the Manager
will then become entitled to a performance incentive fee of 2% of the FAV.
Should cash dividends (excluding 1.0p of the special dividend) of an aggregate
amount equal to 40% or more of the FAV (net of 1.0p of the special interim
dividend) be paid or declared by the same date, the Manager will then become
entitled to an additional performance incentive fee of a further 1% of the FAV.
QCML also provides administrative and secretarial services to the Company. For
the period prior to the merger it was entitled to a fee of £44,000 per annum
(based on an amount adjusted in line with the RPI), which was pro rated to
reflect a four month period. Following the merger the fee was increased to an
annual amount of £60,000, to be adjusted annually in line with changes in the
RPI. The resulting fee for the year amounted to £55,000, as stated in note 4.
4. Other expenses
2005
2006 (13 months)
£'000 £'000
Administration and secretarial services 55 46
Directors' remuneration (note 5) 52 42
Auditor's remuneration
audit services 14 18
non audit services 9 8
Legal and professional expenses 47 29
Insurance 32 17
UKLA, LSE and registrar's fees 38 19
Management fees payable to OLIM Limited 44 -
Transaction costs 20 -
Irrecoverable VAT 146 82
Other 29 24
486 285
5. Directors remuneration
2005
2006 (13 months)
£'000 £'000
Fees paid to directors 4 13
Amounts paid to third parties, excluding VAT, in 48 29
consideration of the services of directors
52 42
6. Tax on ordinary activities
2005
2006 (13 months)
£'000 £'000
Corporation tax payable - -
Reconciliation of profit on ordinary activities to
taxation
Profit/(loss) on ordinary activities before tax 2,862 (2,037)
Tax on profit on ordinary activities at standard UK 859 (611)
corporation tax rate of 30% (2005: 30%)
Effects of:
Non-taxable items (1,107) 131
Unutilised expenses 248 480
Corporation tax payable - -
7. Dividends paid and proposed
2005
2006 (13 months)
£'000 £'000
Interim dividend: 1.25p per share paid 11 November 2005 1,529 -
The directors have proposed a final dividend of 2.5p per share, equivalent to £
2,996,000, in respect of the year ended 28 February 2006, which, if approved by
shareholders, would be payable on 3 July 2006.
8. Profit per share
The profit per share of 3.3p (2005: loss of 5.9p) is based on the profit on
ordinary activities after tax of £2,862,000 (2005: loss of £2,037,000) and on
the weighted average number of ordinary shares in issue during the year of
85,789,025 (2005: 33,699,680). There is no dilution effect in respect of the
year ended 28 February 2006 (2005: £nil).
9. Net asset value
The calculation of net asset value per share as at 28 February 2006 of 44.5p
(2005: 44.1p) is based on net assets of £53,335,000 (2005: £14,651,000) divided
by the 119,848,625 ordinary shares in issue at that date (2005: 33,227,610).
There is no dilution effect in respect of the year ended 28 February 2006
(2005: nil).
This preliminary statement, which has been agreed with the auditors, was
approved by the Board on 16 May 2006. It is not the company's statutory
accounts. The statutory accounts for the year ended 28 February 2005 have been
delivered to the Registrar of Companies and received an audit report which was
unqualified, did not include a reference to any matters to which the auditors
drew attention by way of emphasis without qualifying the report, and did not
contain statements under section 237(2) and (3) of the Companies Act 1985. The
statutory accounts for the year ended 28 February 2006 have not yet been
approved, audited or filed.
A copy of the above document will be submitted to the UK Listing Authority, and
will shortly be available for inspection at the UK Listing Authority's Document
Viewing Facility, which is situated at:
Financial Services Authority
25 The North Colonnade
Canary Wharf
London
E14 5HS
Copies of the full financial statements for the period ended 28 February 2006
are expected to be posted to shareholders on 19 May 2006 and will be available
to the public at the registered office of the Company at 29 Queen Anne's Gate,
London, SW1H 9BU.
Latest directors dealings
- 1 day ago Legal & General Group
- 1 day ago Legal & General Group
- 2 days ago GETECH Group
- 2 days ago Great Portland Estates
- 2 days ago Time Out Group